SOPHiA GENETICS SA
SOPH Healthcare Health Information Services
SOPHiA GENETICS SA’s revenue for fiscal 2025 (year ended December 2025) was $77.3 million, up 18.6% from fiscal 2024. In the quarter to June 2026, revenue grew 27.2%, EPS grew 9.88%, free cash flow grew 6.50% and total debt rose 1.12%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow SOPH
SOPHiA GENETICS SA (SOPH) EV/Sales
As of 16 October 2026, SOPHiA GENETICS SA (SOPH) trades at a EV/Sales of 5.1×. Over the past ten years it has ranged from −1.7× (June 2022) to 26.6× (August 2021); the current reading is higher than 82% of that period. That is above the Health Information Services industry median of 2.6× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.8× | 80.71% |
| FY2024 | 2.1× | (36.17%) |
| FY2023 | 3.3× | — |
| FY2022 | −0.4× | — |
| FY2021 | 13.0× | (41.39%) |
| FY2020 | 22.2× | 0.00% |
| FY2019 | 22.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.3× | 3.12% |
| Mar 2026 | 4.1× | 8.67% |
| Dec 2025 | 3.8× | (3.76%) |
| Sep 2025 | 4.0× | 69.34% |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDRX Veradigm Inc. compare | 0.6× |
| EVH Evolent Health, Inc compare | 0.6× |
| PHR Phreesia, Inc. compare | 1.5× |
| WEAV Weave Communications, Inc. compare | 2.0× |
| HSTM HealthStream, Inc. compare | 2.9× |
| NRC National Research Corporation compare | 3.8× |
| CARL Carlsmed, Inc. compare | 4.6× |
| CTEV Claritev Corporation compare | 5.0× |
| SOPH SOPHiA GENETICS SA | 5.1× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)